|

PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine Clinical Trials

1 actively recruiting trial

Also known as: Azacitidine (5-Azacytidine, Ladakamycin), Decitabine (Dacogen, 5-aza-2-deoxycytidine), PD-1 inhibitor (Tislelizumab), Venetoclax (ABT-199, GDC-0199)

Pipeline

Phase 2: 1

Top Sponsors

  • Beijing 302 Hospital1

Indications

  • Relapsed Acute Myeloid Leukemia1
  • Minimal Residual Disease1
  • Refractory Acute Myeloid Leukemia1
  • Myelodysplastic Syndromes1
  • Cancer1

Other1 trial

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.